The France Al in Clinical Trials Market was valued at $24.26 Million in 2024 and projected to reach to $47.25 Million by 2029, representing a compound annual growth rate of CAGR 11.7%. France's AI in Clinical Trials market is poised for sustained expansion as healthcare providers and pharmaceutical companies increasingly adopt intelligent solutions to optimize trial efficiency and reduce operational costs.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
France's AI in Clinical Trials market is valued at USD 24.26 million in 2024, with a projected CAGR of 11.7%, reaching USD 47.25 million by 2029, demonstrating strong double-digit growth momentum.
France is establishing itself as a key European hub for AI-driven clinical research, leveraging its advanced healthcare infrastructure and regulatory framework to attract international clinical trial investments.
The French government's commitment to digital health transformation is accelerating AI adoption in clinical trials, with increased funding for research institutions and pharmaceutical companies implementing intelligent trial management solutions.
France's progressive regulatory environment and alignment with EU guidelines create favorable conditions for AI implementation in clinical research, fostering innovation while maintaining stringent data protection standards.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | DRUG REPURPOSING (Function) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 12.4% from 2024 to 2029 |
| Largest Segment | CLOUD-BASED SOLUTIONS (Deployment Mode) |
| Market Size Base Year (Billions) | ~USD 1.36 (2024) |
| Revenue Forecast (Billions) | ~USD 2.44 (2029) |
| Segments Covered | Offering, Function, Type, Phase, Deployment Mode, Indication, Technology, Application, End User |
9 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| CONTRACT RESEARCH ORGANIZATIONS | 5.17 | 5.82 | 6.56 | 7.39 | 8.32 | 9.36 | 10.53 | 11.84 | 13.3 | 12.5 |
| HEALTHCARE PROVIDERS | 7.63 | 8.45 | 9.35 | 10.34 | 11.43 | 12.63 | 13.96 | 15.42 | 17.02 | 10.5 |
| MEDICAL DEVICE MANUFACTURERS | 6.21 | 7.12 | 8.16 | 9.35 | 10.71 | 12.26 | 14.03 | 16.04 | 18.34 | 14.4 |
| PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES | 22.33 | 24.92 | 27.81 | 31.02 | 34.58 | 38.54 | 42.93 | 47.8 | 53.21 | 11.4 |
| RESEARCH INSTITUTES & LABORATORIES | 10.47 | 11.9 | 13.53 | 15.37 | 17.45 | 19.81 | 22.48 | 25.5 | 28.91 | 13.5 |
| TOTAL | 51.81 | 58.22 | 65.41 | 73.46 | 82.49 | 92.6 | 103.92 | 116.59 | 130.79 | 12.2 |
France's AI in Clinical Trials market was valued at USD 24.26 million in 2024 and is expected to reach USD 47.25 million by 2029.
France's AI in Clinical Trials market is growing at a compound annual growth rate (CAGR) of 11.7% from 2024 to 2029.
France's growth is driven by increasing demand for trial efficiency, patient recruitment optimization, regulatory support, and the country's strong pharmaceutical industry presence.
France represents a significant portion of European AI in Clinical Trials adoption, with its 11.7% CAGR reflecting strong market momentum and investment in healthcare innovation.
France's market includes pharmaceutical companies, contract research organizations (CROs), academic medical centers, and healthcare technology providers integrating AI solutions into trial operations.
The study involved significant activities to estimate the current size of the AI in clinical trials market. Exhaustive secondary research was done to collect information on the AI in clinical trials market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in clinical trials market.
This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in clinical trials solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.
Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in clinical trials vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.
In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the AI in clinical trials market.
After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of AI in clinical trials solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.
In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.
Breakdown of Primary Participants:
Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in clinical trials market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.
The AI in clinical trials market refers to the utilization of artificial intelligence-based tools to improve the different phases as well as steps of clinical research process activity such as trial development, enrolment of patients, data management and analysis and therapeutic monitoring. Al assists in accomplishing such tasks by automating the collection of data, enhancing the efficiency of patient matching and improving prediction of outcomes of trials which in turn helps in reducing the timeline and cost associated with these processes. This allows for a clearer understanding of large amounts of information, for example, within patient charts or genome information, so that the appropriate information is available for making decisions for particular trials. Clinical trials become highly efficient, cheaper, and more precise with the integration of Al technologies into the processes which significantly helps in drug development reducing the waiting time and the success rate improves. With more and more applications of AI in the healthcare sector, this healthcare services market is projected to grow as there will be a rise in the need for improved clinical research within a short turnaround time.
Full forecast, segment splits, and company analysis for all AI in Clinical Trials Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report